46 patients from the US, UK, and Canada have been taking part in a clinical trial in Toronto in hopes of finding a cure for Huntington's disease. The therapy targets and stifles the mutant huntingtin (HTT) gene that causes the toxic proteins responsible for the disease. Scientists around the world remain hopeful as the trial shifts into Phase 3, which will involve an injection in the patient's spine that could stop all negative activity of the mutant HTT gene.